nodes	percent_of_prediction	percent_of_DWPC	metapath
Melphalan—Alkylating Activity—Temozolomide—skin cancer	0.347	0.556	CiPCiCtD
Melphalan—peripheral nervous system neoplasm—skin cancer	0.314	1	CtDrD
Melphalan—Alkylating Activity—Dacarbazine—skin cancer	0.277	0.444	CiPCiCtD
Melphalan—SLC7A5—nipple—skin cancer	0.000814	0.133	CbGeAlD
Melphalan—SLC7A5—connective tissue—skin cancer	0.000577	0.0944	CbGeAlD
Melphalan—SLC7A5—epithelium—skin cancer	0.000548	0.0896	CbGeAlD
Melphalan—SLC7A5—skin of body—skin cancer	0.000521	0.0853	CbGeAlD
Melphalan—SLC22A3—nipple—skin cancer	0.000505	0.0826	CbGeAlD
Melphalan—SLC7A5—mammalian vulva—skin cancer	0.000475	0.0778	CbGeAlD
Melphalan—SLC7A5—lymphoid tissue—skin cancer	0.000422	0.069	CbGeAlD
Melphalan—SLC7A5—female reproductive system—skin cancer	0.000407	0.0666	CbGeAlD
Melphalan—SLC22A3—connective tissue—skin cancer	0.000358	0.0586	CbGeAlD
Melphalan—SLC7A5—head—skin cancer	0.00034	0.0556	CbGeAlD
Melphalan—SLC22A3—mammalian vulva—skin cancer	0.000295	0.0483	CbGeAlD
Melphalan—SLC22A3—female reproductive system—skin cancer	0.000253	0.0413	CbGeAlD
Melphalan—SLC7A5—lymph node—skin cancer	0.000238	0.039	CbGeAlD
Melphalan—SLC22A3—head—skin cancer	0.000211	0.0345	CbGeAlD
Melphalan—Pruritus—Vismodegib—skin cancer	0.000171	0.00308	CcSEcCtD
Melphalan—Flushing—Imiquimod—skin cancer	0.000166	0.00299	CcSEcCtD
Melphalan—Diarrhoea—Vismodegib—skin cancer	0.000165	0.00297	CcSEcCtD
Melphalan—Extravasation—Docetaxel—skin cancer	0.000163	0.00293	CcSEcCtD
Melphalan—Immune system disorder—Imiquimod—skin cancer	0.000162	0.00291	CcSEcCtD
Melphalan—Amenorrhoea—Docetaxel—skin cancer	0.000162	0.00291	CcSEcCtD
Melphalan—Mediastinal disorder—Imiquimod—skin cancer	0.000161	0.00291	CcSEcCtD
Melphalan—Arrhythmia—Imiquimod—skin cancer	0.00016	0.00288	CcSEcCtD
Melphalan—Cough—Vemurafenib—skin cancer	0.00016	0.00287	CcSEcCtD
Melphalan—Liver function test abnormal—Dactinomycin—skin cancer	0.000158	0.00285	CcSEcCtD
Melphalan—Alopecia—Imiquimod—skin cancer	0.000158	0.00285	CcSEcCtD
Melphalan—Bronchospasm—Bleomycin—skin cancer	0.000156	0.00282	CcSEcCtD
Melphalan—Myalgia—Vemurafenib—skin cancer	0.000156	0.0028	CcSEcCtD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.000155	0.00278	CcSEcCtD
Melphalan—Vomiting—Vismodegib—skin cancer	0.000154	0.00276	CcSEcCtD
Melphalan—Rash—Vismodegib—skin cancer	0.000152	0.00274	CcSEcCtD
Melphalan—Dermatitis—Vismodegib—skin cancer	0.000152	0.00274	CcSEcCtD
Melphalan—Pancytopenia—Bleomycin—skin cancer	0.000151	0.00272	CcSEcCtD
Melphalan—Anaphylactic shock—Vemurafenib—skin cancer	0.000149	0.00269	CcSEcCtD
Melphalan—Infection—Vemurafenib—skin cancer	0.000148	0.00267	CcSEcCtD
Melphalan—SLC22A3—lymph node—skin cancer	0.000148	0.0242	CbGeAlD
Melphalan—Skin disorder—Vemurafenib—skin cancer	0.000145	0.00261	CcSEcCtD
Melphalan—Nausea—Vismodegib—skin cancer	0.000144	0.00258	CcSEcCtD
Melphalan—Hepatocellular injury—Docetaxel—skin cancer	0.000142	0.00256	CcSEcCtD
Melphalan—Injection site reaction—Docetaxel—skin cancer	0.000141	0.00254	CcSEcCtD
Melphalan—Pancytopenia—Dactinomycin—skin cancer	0.000141	0.00253	CcSEcCtD
Melphalan—Hypotension—Vemurafenib—skin cancer	0.000139	0.00251	CcSEcCtD
Melphalan—Neutropenia—Dactinomycin—skin cancer	0.000139	0.0025	CcSEcCtD
Melphalan—Stomatitis—Bleomycin—skin cancer	0.000138	0.00249	CcSEcCtD
Melphalan—Cough—Imiquimod—skin cancer	0.000136	0.00245	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.000136	0.00245	CcSEcCtD
Melphalan—Cardiac arrest—Fluorouracil—skin cancer	0.000136	0.00245	CcSEcCtD
Melphalan—Skin exfoliation—Docetaxel—skin cancer	0.000136	0.00244	CcSEcCtD
Melphalan—Convulsion—Imiquimod—skin cancer	0.000135	0.00243	CcSEcCtD
Melphalan—Neuropathy—Docetaxel—skin cancer	0.000134	0.0024	CcSEcCtD
Melphalan—Myalgia—Imiquimod—skin cancer	0.000133	0.00239	CcSEcCtD
Melphalan—Chest pain—Imiquimod—skin cancer	0.000133	0.00239	CcSEcCtD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.000132	0.00237	CcSEcCtD
Melphalan—Decreased appetite—Vemurafenib—skin cancer	0.00013	0.00234	CcSEcCtD
Melphalan—Stomatitis—Dactinomycin—skin cancer	0.000129	0.00232	CcSEcCtD
Melphalan—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000129	0.00232	CcSEcCtD
Melphalan—Fatigue—Vemurafenib—skin cancer	0.000129	0.00232	CcSEcCtD
Melphalan—Neoplasm—Docetaxel—skin cancer	0.000129	0.00231	CcSEcCtD
Melphalan—Haemoglobin—Bleomycin—skin cancer	0.000128	0.0023	CcSEcCtD
Melphalan—Pancytopenia—Temozolomide—skin cancer	0.000127	0.00229	CcSEcCtD
Melphalan—Oedema—Imiquimod—skin cancer	0.000127	0.00229	CcSEcCtD
Melphalan—Haemorrhage—Bleomycin—skin cancer	0.000127	0.00229	CcSEcCtD
Melphalan—Infection—Imiquimod—skin cancer	0.000126	0.00228	CcSEcCtD
Melphalan—Neutropenia—Temozolomide—skin cancer	0.000125	0.00226	CcSEcCtD
Melphalan—Tachycardia—Imiquimod—skin cancer	0.000124	0.00224	CcSEcCtD
Melphalan—Skin disorder—Imiquimod—skin cancer	0.000124	0.00223	CcSEcCtD
Melphalan—Anorexia—Imiquimod—skin cancer	0.000121	0.00218	CcSEcCtD
Melphalan—Hepatitis—Dactinomycin—skin cancer	0.000119	0.00214	CcSEcCtD
Melphalan—Flushing—Bleomycin—skin cancer	0.000118	0.00213	CcSEcCtD
Melphalan—Pancytopenia—Fluorouracil—skin cancer	0.000117	0.00211	CcSEcCtD
Melphalan—Neuropathy peripheral—Temozolomide—skin cancer	0.000117	0.00211	CcSEcCtD
Melphalan—Stomatitis—Temozolomide—skin cancer	0.000117	0.0021	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Imiquimod—skin cancer	0.000116	0.00209	CcSEcCtD
Melphalan—Paraesthesia—Imiquimod—skin cancer	0.000114	0.00206	CcSEcCtD
Melphalan—Dyspnoea—Imiquimod—skin cancer	0.000113	0.00204	CcSEcCtD
Melphalan—Hepatobiliary disease—Temozolomide—skin cancer	0.000113	0.00204	CcSEcCtD
Melphalan—Alopecia—Bleomycin—skin cancer	0.000112	0.00202	CcSEcCtD
Melphalan—Dyspepsia—Imiquimod—skin cancer	0.000112	0.00202	CcSEcCtD
Melphalan—Decreased appetite—Imiquimod—skin cancer	0.000111	0.00199	CcSEcCtD
Melphalan—Flushing—Dactinomycin—skin cancer	0.00011	0.00198	CcSEcCtD
Melphalan—Hypersensitivity—Vemurafenib—skin cancer	0.00011	0.00198	CcSEcCtD
Melphalan—Gastrointestinal disorder—Imiquimod—skin cancer	0.00011	0.00198	CcSEcCtD
Melphalan—Fatigue—Imiquimod—skin cancer	0.00011	0.00198	CcSEcCtD
Melphalan—Atrial fibrillation—Docetaxel—skin cancer	0.000109	0.00196	CcSEcCtD
Melphalan—Pain—Imiquimod—skin cancer	0.000109	0.00196	CcSEcCtD
Melphalan—Neuropathy peripheral—Fluorouracil—skin cancer	0.000108	0.00194	CcSEcCtD
Melphalan—Haemoglobin—Temozolomide—skin cancer	0.000108	0.00194	CcSEcCtD
Melphalan—Stomatitis—Fluorouracil—skin cancer	0.000107	0.00193	CcSEcCtD
Melphalan—Haemorrhage—Temozolomide—skin cancer	0.000107	0.00193	CcSEcCtD
Melphalan—Hepatitis—Temozolomide—skin cancer	0.000107	0.00193	CcSEcCtD
Melphalan—Asthenia—Vemurafenib—skin cancer	0.000107	0.00193	CcSEcCtD
Melphalan—Urinary tract disorder—Temozolomide—skin cancer	0.000106	0.00191	CcSEcCtD
Melphalan—Pruritus—Vemurafenib—skin cancer	0.000106	0.0019	CcSEcCtD
Melphalan—Connective tissue disorder—Temozolomide—skin cancer	0.000106	0.0019	CcSEcCtD
Melphalan—Urethral disorder—Temozolomide—skin cancer	0.000105	0.00189	CcSEcCtD
Melphalan—Alopecia—Dactinomycin—skin cancer	0.000105	0.00189	CcSEcCtD
Melphalan—Hyponatraemia—Docetaxel—skin cancer	0.000104	0.00186	CcSEcCtD
Melphalan—Anaemia—Bleomycin—skin cancer	0.000102	0.00184	CcSEcCtD
Melphalan—Diarrhoea—Vemurafenib—skin cancer	0.000102	0.00184	CcSEcCtD
Melphalan—Urticaria—Imiquimod—skin cancer	0.000101	0.00182	CcSEcCtD
Melphalan—Flushing—Temozolomide—skin cancer	9.97e-05	0.00179	CcSEcCtD
Melphalan—Haemoglobin—Fluorouracil—skin cancer	9.94e-05	0.00179	CcSEcCtD
Melphalan—Leukopenia—Bleomycin—skin cancer	9.92e-05	0.00178	CcSEcCtD
Melphalan—Haemorrhage—Fluorouracil—skin cancer	9.89e-05	0.00178	CcSEcCtD
Melphalan—Immune system disorder—Temozolomide—skin cancer	9.7e-05	0.00175	CcSEcCtD
Melphalan—Mediastinal disorder—Temozolomide—skin cancer	9.68e-05	0.00174	CcSEcCtD
Melphalan—Cough—Bleomycin—skin cancer	9.67e-05	0.00174	CcSEcCtD
Melphalan—Anaemia—Dactinomycin—skin cancer	9.55e-05	0.00172	CcSEcCtD
Melphalan—Liver function test abnormal—Docetaxel—skin cancer	9.53e-05	0.00171	CcSEcCtD
Melphalan—Vomiting—Vemurafenib—skin cancer	9.49e-05	0.00171	CcSEcCtD
Melphalan—Alopecia—Temozolomide—skin cancer	9.49e-05	0.00171	CcSEcCtD
Melphalan—Chest pain—Bleomycin—skin cancer	9.43e-05	0.0017	CcSEcCtD
Melphalan—Myalgia—Bleomycin—skin cancer	9.43e-05	0.0017	CcSEcCtD
Melphalan—Rash—Vemurafenib—skin cancer	9.41e-05	0.00169	CcSEcCtD
Melphalan—Dermatitis—Vemurafenib—skin cancer	9.4e-05	0.00169	CcSEcCtD
Melphalan—Hypersensitivity—Imiquimod—skin cancer	9.38e-05	0.00169	CcSEcCtD
Melphalan—Leukopenia—Dactinomycin—skin cancer	9.25e-05	0.00166	CcSEcCtD
Melphalan—Asthenia—Imiquimod—skin cancer	9.13e-05	0.00164	CcSEcCtD
Melphalan—Anaphylactic shock—Bleomycin—skin cancer	9.04e-05	0.00163	CcSEcCtD
Melphalan—Oedema—Bleomycin—skin cancer	9.04e-05	0.00163	CcSEcCtD
Melphalan—Pruritus—Imiquimod—skin cancer	9.01e-05	0.00162	CcSEcCtD
Melphalan—Infection—Bleomycin—skin cancer	8.98e-05	0.00162	CcSEcCtD
Melphalan—Nausea—Vemurafenib—skin cancer	8.87e-05	0.0016	CcSEcCtD
Melphalan—Thrombocytopenia—Bleomycin—skin cancer	8.86e-05	0.00159	CcSEcCtD
Melphalan—Arrhythmia—Fluorouracil—skin cancer	8.84e-05	0.00159	CcSEcCtD
Melphalan—Myalgia—Dactinomycin—skin cancer	8.8e-05	0.00158	CcSEcCtD
Melphalan—Bronchospasm—Docetaxel—skin cancer	8.78e-05	0.00158	CcSEcCtD
Melphalan—Alopecia—Fluorouracil—skin cancer	8.74e-05	0.00157	CcSEcCtD
Melphalan—Diarrhoea—Imiquimod—skin cancer	8.71e-05	0.00157	CcSEcCtD
Melphalan—Anaemia—Temozolomide—skin cancer	8.64e-05	0.00155	CcSEcCtD
Melphalan—Anorexia—Bleomycin—skin cancer	8.62e-05	0.00155	CcSEcCtD
Melphalan—Pancytopenia—Docetaxel—skin cancer	8.47e-05	0.00152	CcSEcCtD
Melphalan—Hypotension—Bleomycin—skin cancer	8.45e-05	0.00152	CcSEcCtD
Melphalan—Oedema—Dactinomycin—skin cancer	8.43e-05	0.00152	CcSEcCtD
Melphalan—Infection—Dactinomycin—skin cancer	8.38e-05	0.00151	CcSEcCtD
Melphalan—Leukopenia—Temozolomide—skin cancer	8.37e-05	0.00151	CcSEcCtD
Melphalan—Neutropenia—Docetaxel—skin cancer	8.34e-05	0.0015	CcSEcCtD
Melphalan—Thrombocytopenia—Dactinomycin—skin cancer	8.26e-05	0.00149	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Bleomycin—skin cancer	8.24e-05	0.00148	CcSEcCtD
Melphalan—Cough—Temozolomide—skin cancer	8.16e-05	0.00147	CcSEcCtD
Melphalan—Paraesthesia—Bleomycin—skin cancer	8.12e-05	0.00146	CcSEcCtD
Melphalan—Convulsion—Temozolomide—skin cancer	8.1e-05	0.00146	CcSEcCtD
Melphalan—Vomiting—Imiquimod—skin cancer	8.09e-05	0.00146	CcSEcCtD
Melphalan—Dyspnoea—Bleomycin—skin cancer	8.06e-05	0.00145	CcSEcCtD
Melphalan—Anorexia—Dactinomycin—skin cancer	8.04e-05	0.00145	CcSEcCtD
Melphalan—Rash—Imiquimod—skin cancer	8.03e-05	0.00144	CcSEcCtD
Melphalan—Dermatitis—Imiquimod—skin cancer	8.02e-05	0.00144	CcSEcCtD
Melphalan—Anaemia—Fluorouracil—skin cancer	7.96e-05	0.00143	CcSEcCtD
Melphalan—Myalgia—Temozolomide—skin cancer	7.96e-05	0.00143	CcSEcCtD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	7.9e-05	0.00142	CcSEcCtD
Melphalan—Decreased appetite—Bleomycin—skin cancer	7.86e-05	0.00141	CcSEcCtD
Melphalan—Neuropathy peripheral—Docetaxel—skin cancer	7.8e-05	0.0014	CcSEcCtD
Melphalan—Jaundice—Docetaxel—skin cancer	7.75e-05	0.0014	CcSEcCtD
Melphalan—Stomatitis—Docetaxel—skin cancer	7.75e-05	0.0014	CcSEcCtD
Melphalan—Pain—Bleomycin—skin cancer	7.73e-05	0.00139	CcSEcCtD
Melphalan—Leukopenia—Fluorouracil—skin cancer	7.71e-05	0.00139	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Dactinomycin—skin cancer	7.68e-05	0.00138	CcSEcCtD
Melphalan—Oedema—Temozolomide—skin cancer	7.63e-05	0.00137	CcSEcCtD
Melphalan—Anaphylactic shock—Temozolomide—skin cancer	7.63e-05	0.00137	CcSEcCtD
Melphalan—Infection—Temozolomide—skin cancer	7.58e-05	0.00136	CcSEcCtD
Melphalan—Nausea—Imiquimod—skin cancer	7.56e-05	0.00136	CcSEcCtD
Melphalan—Hepatobiliary disease—Docetaxel—skin cancer	7.52e-05	0.00135	CcSEcCtD
Melphalan—Thrombocytopenia—Temozolomide—skin cancer	7.47e-05	0.00134	CcSEcCtD
Melphalan—Convulsion—Fluorouracil—skin cancer	7.46e-05	0.00134	CcSEcCtD
Melphalan—Skin disorder—Temozolomide—skin cancer	7.41e-05	0.00133	CcSEcCtD
Melphalan—Chest pain—Fluorouracil—skin cancer	7.33e-05	0.00132	CcSEcCtD
Melphalan—Myalgia—Fluorouracil—skin cancer	7.33e-05	0.00132	CcSEcCtD
Melphalan—Decreased appetite—Dactinomycin—skin cancer	7.33e-05	0.00132	CcSEcCtD
Melphalan—Fatigue—Dactinomycin—skin cancer	7.27e-05	0.00131	CcSEcCtD
Melphalan—Anorexia—Temozolomide—skin cancer	7.27e-05	0.00131	CcSEcCtD
Melphalan—Pain—Dactinomycin—skin cancer	7.21e-05	0.0013	CcSEcCtD
Melphalan—Urticaria—Bleomycin—skin cancer	7.18e-05	0.00129	CcSEcCtD
Melphalan—Haemoglobin—Docetaxel—skin cancer	7.18e-05	0.00129	CcSEcCtD
Melphalan—Haemorrhage—Docetaxel—skin cancer	7.14e-05	0.00128	CcSEcCtD
Melphalan—Hepatitis—Docetaxel—skin cancer	7.14e-05	0.00128	CcSEcCtD
Melphalan—Urinary tract disorder—Docetaxel—skin cancer	7.05e-05	0.00127	CcSEcCtD
Melphalan—Anaphylactic shock—Fluorouracil—skin cancer	7.03e-05	0.00126	CcSEcCtD
Melphalan—Oedema—Fluorouracil—skin cancer	7.03e-05	0.00126	CcSEcCtD
Melphalan—Connective tissue disorder—Docetaxel—skin cancer	7.02e-05	0.00126	CcSEcCtD
Melphalan—Urethral disorder—Docetaxel—skin cancer	7e-05	0.00126	CcSEcCtD
Melphalan—Infection—Fluorouracil—skin cancer	6.98e-05	0.00126	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Temozolomide—skin cancer	6.95e-05	0.00125	CcSEcCtD
Melphalan—Thrombocytopenia—Fluorouracil—skin cancer	6.88e-05	0.00124	CcSEcCtD
Melphalan—Tachycardia—Fluorouracil—skin cancer	6.86e-05	0.00123	CcSEcCtD
Melphalan—Paraesthesia—Temozolomide—skin cancer	6.85e-05	0.00123	CcSEcCtD
Melphalan—Dyspnoea—Temozolomide—skin cancer	6.8e-05	0.00122	CcSEcCtD
Melphalan—Dyspepsia—Temozolomide—skin cancer	6.72e-05	0.00121	CcSEcCtD
Melphalan—Anorexia—Fluorouracil—skin cancer	6.7e-05	0.00121	CcSEcCtD
Melphalan—Hypersensitivity—Bleomycin—skin cancer	6.66e-05	0.0012	CcSEcCtD
Melphalan—Decreased appetite—Temozolomide—skin cancer	6.63e-05	0.00119	CcSEcCtD
Melphalan—Flushing—Docetaxel—skin cancer	6.63e-05	0.00119	CcSEcCtD
Melphalan—Gastrointestinal disorder—Temozolomide—skin cancer	6.59e-05	0.00119	CcSEcCtD
Melphalan—Fatigue—Temozolomide—skin cancer	6.58e-05	0.00118	CcSEcCtD
Melphalan—Hypotension—Fluorouracil—skin cancer	6.57e-05	0.00118	CcSEcCtD
Melphalan—Pain—Temozolomide—skin cancer	6.52e-05	0.00117	CcSEcCtD
Melphalan—Asthenia—Bleomycin—skin cancer	6.49e-05	0.00117	CcSEcCtD
Melphalan—Immune system disorder—Docetaxel—skin cancer	6.45e-05	0.00116	CcSEcCtD
Melphalan—Mediastinal disorder—Docetaxel—skin cancer	6.44e-05	0.00116	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Fluorouracil—skin cancer	6.4e-05	0.00115	CcSEcCtD
Melphalan—Pruritus—Bleomycin—skin cancer	6.4e-05	0.00115	CcSEcCtD
Melphalan—Arrhythmia—Docetaxel—skin cancer	6.38e-05	0.00115	CcSEcCtD
Melphalan—Paraesthesia—Fluorouracil—skin cancer	6.31e-05	0.00114	CcSEcCtD
Melphalan—Alopecia—Docetaxel—skin cancer	6.31e-05	0.00114	CcSEcCtD
Melphalan—Dyspnoea—Fluorouracil—skin cancer	6.27e-05	0.00113	CcSEcCtD
Melphalan—Hypersensitivity—Dactinomycin—skin cancer	6.21e-05	0.00112	CcSEcCtD
Melphalan—Dyspepsia—Fluorouracil—skin cancer	6.19e-05	0.00111	CcSEcCtD
Melphalan—Decreased appetite—Fluorouracil—skin cancer	6.11e-05	0.0011	CcSEcCtD
Melphalan—Gastrointestinal disorder—Fluorouracil—skin cancer	6.07e-05	0.00109	CcSEcCtD
Melphalan—Urticaria—Temozolomide—skin cancer	6.06e-05	0.00109	CcSEcCtD
Melphalan—Asthenia—Dactinomycin—skin cancer	6.05e-05	0.00109	CcSEcCtD
Melphalan—Pain—Fluorouracil—skin cancer	6.01e-05	0.00108	CcSEcCtD
Melphalan—Diarrhoea—Dactinomycin—skin cancer	5.77e-05	0.00104	CcSEcCtD
Melphalan—Vomiting—Bleomycin—skin cancer	5.75e-05	0.00103	CcSEcCtD
Melphalan—Anaemia—Docetaxel—skin cancer	5.75e-05	0.00103	CcSEcCtD
Melphalan—Rash—Bleomycin—skin cancer	5.7e-05	0.00103	CcSEcCtD
Melphalan—Dermatitis—Bleomycin—skin cancer	5.7e-05	0.00103	CcSEcCtD
Melphalan—Hypersensitivity—Temozolomide—skin cancer	5.62e-05	0.00101	CcSEcCtD
Melphalan—Urticaria—Fluorouracil—skin cancer	5.58e-05	0.001	CcSEcCtD
Melphalan—Leukopenia—Docetaxel—skin cancer	5.56e-05	0.001	CcSEcCtD
Melphalan—Asthenia—Temozolomide—skin cancer	5.47e-05	0.000985	CcSEcCtD
Melphalan—Cough—Docetaxel—skin cancer	5.42e-05	0.000976	CcSEcCtD
Melphalan—Pruritus—Temozolomide—skin cancer	5.4e-05	0.000971	CcSEcCtD
Melphalan—Convulsion—Docetaxel—skin cancer	5.39e-05	0.000969	CcSEcCtD
Melphalan—Nausea—Bleomycin—skin cancer	5.37e-05	0.000967	CcSEcCtD
Melphalan—Vomiting—Dactinomycin—skin cancer	5.36e-05	0.000965	CcSEcCtD
Melphalan—Rash—Dactinomycin—skin cancer	5.32e-05	0.000957	CcSEcCtD
Melphalan—Chest pain—Docetaxel—skin cancer	5.29e-05	0.000952	CcSEcCtD
Melphalan—Myalgia—Docetaxel—skin cancer	5.29e-05	0.000952	CcSEcCtD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	5.26e-05	0.000946	CcSEcCtD
Melphalan—Diarrhoea—Temozolomide—skin cancer	5.22e-05	0.000939	CcSEcCtD
Melphalan—Hypersensitivity—Fluorouracil—skin cancer	5.18e-05	0.000932	CcSEcCtD
Melphalan—Anaphylactic shock—Docetaxel—skin cancer	5.07e-05	0.000913	CcSEcCtD
Melphalan—Oedema—Docetaxel—skin cancer	5.07e-05	0.000913	CcSEcCtD
Melphalan—Infection—Docetaxel—skin cancer	5.04e-05	0.000907	CcSEcCtD
Melphalan—Nausea—Dactinomycin—skin cancer	5.01e-05	0.000902	CcSEcCtD
Melphalan—Pruritus—Fluorouracil—skin cancer	4.97e-05	0.000895	CcSEcCtD
Melphalan—Thrombocytopenia—Docetaxel—skin cancer	4.97e-05	0.000894	CcSEcCtD
Melphalan—Tachycardia—Docetaxel—skin cancer	4.95e-05	0.000891	CcSEcCtD
Melphalan—Skin disorder—Docetaxel—skin cancer	4.93e-05	0.000887	CcSEcCtD
Melphalan—Vomiting—Temozolomide—skin cancer	4.85e-05	0.000873	CcSEcCtD
Melphalan—Anorexia—Docetaxel—skin cancer	4.84e-05	0.00087	CcSEcCtD
Melphalan—Rash—Temozolomide—skin cancer	4.81e-05	0.000866	CcSEcCtD
Melphalan—Diarrhoea—Fluorouracil—skin cancer	4.81e-05	0.000865	CcSEcCtD
Melphalan—Dermatitis—Temozolomide—skin cancer	4.81e-05	0.000865	CcSEcCtD
Melphalan—Hypotension—Docetaxel—skin cancer	4.74e-05	0.000853	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Docetaxel—skin cancer	4.62e-05	0.000832	CcSEcCtD
Melphalan—Paraesthesia—Docetaxel—skin cancer	4.56e-05	0.00082	CcSEcCtD
Melphalan—Nausea—Temozolomide—skin cancer	4.53e-05	0.000815	CcSEcCtD
Melphalan—Dyspnoea—Docetaxel—skin cancer	4.52e-05	0.000814	CcSEcCtD
Melphalan—Vomiting—Fluorouracil—skin cancer	4.47e-05	0.000804	CcSEcCtD
Melphalan—Dyspepsia—Docetaxel—skin cancer	4.47e-05	0.000804	CcSEcCtD
Melphalan—Rash—Fluorouracil—skin cancer	4.43e-05	0.000798	CcSEcCtD
Melphalan—Dermatitis—Fluorouracil—skin cancer	4.43e-05	0.000797	CcSEcCtD
Melphalan—Decreased appetite—Docetaxel—skin cancer	4.41e-05	0.000794	CcSEcCtD
Melphalan—Gastrointestinal disorder—Docetaxel—skin cancer	4.38e-05	0.000788	CcSEcCtD
Melphalan—Fatigue—Docetaxel—skin cancer	4.37e-05	0.000787	CcSEcCtD
Melphalan—Pain—Docetaxel—skin cancer	4.34e-05	0.000781	CcSEcCtD
Melphalan—Nausea—Fluorouracil—skin cancer	4.18e-05	0.000751	CcSEcCtD
Melphalan—Hypersensitivity—Docetaxel—skin cancer	3.74e-05	0.000673	CcSEcCtD
Melphalan—Asthenia—Docetaxel—skin cancer	3.64e-05	0.000655	CcSEcCtD
Melphalan—Pruritus—Docetaxel—skin cancer	3.59e-05	0.000646	CcSEcCtD
Melphalan—Diarrhoea—Docetaxel—skin cancer	3.47e-05	0.000625	CcSEcCtD
Melphalan—Vomiting—Docetaxel—skin cancer	3.23e-05	0.00058	CcSEcCtD
Melphalan—Rash—Docetaxel—skin cancer	3.2e-05	0.000576	CcSEcCtD
Melphalan—Dermatitis—Docetaxel—skin cancer	3.2e-05	0.000575	CcSEcCtD
Melphalan—Nausea—Docetaxel—skin cancer	3.01e-05	0.000542	CcSEcCtD
